Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Adjuvant Treatment in Gastroesophageal Cancer

October 22nd 2020

Looking Toward the Future in Gastroesophageal Cancer

October 22nd 2020

Toxicity Management in Second Line for Gastric Cancer

October 22nd 2020

Clinical Rationale for Antiangiogenics in Gastric Cancer

October 22nd 2020

Predicting Response With Biomarkers in Gastric Cancers

October 22nd 2020

Applying New Data in the Real-World for GEJ Cancer

October 22nd 2020

ESMO 2020: Practice-Changing Data in Esophageal Cancer

October 22nd 2020

First-Line I/O Successful in Gastric Adenocarcinoma

October 22nd 2020

Treatment Landscape in Gastric Cancers Pre-ESMO 2020

October 22nd 2020

Frontline Treatment in Metastatic Gastric Cancer

October 22nd 2020

Optimal Approach Toward Advanced Gastric Cancers in US

October 22nd 2020

Global Trends in Gastric Cancers

October 22nd 2020

Immunotherapy Investigations Lay Groundwork for Future Research Across GI Cancer Settings

October 21st 2020

Manish A. Shah, MD, FASCO, discusses key clinical trials that have evaluated the utility of pembrolizumab and nivolumab in the gastric/gastroesophageal junction cancer, and esophageal squamous cell carcinoma paradigms.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

Dr. Ocean on Determining Optimal Frontline Treatments for Metastatic Pancreatic Cancer

October 20th 2020

Allyson Ocean, MD, discusses determining the optimal frontline treatment of patients with metastatic pancreatic cancer.

Dr. Brar on the Need to Identify Biomarkers in HCC

October 19th 2020

Gagandeep Brar, MD, discusses the need to identify biomarkers in hepatocellular carcinoma.

DisTinGuish Trial Doses First Patient With Investigational Dickkopf-1 Antibody DKN-01 Plus Tislelizumab in Gastric/GEJ Cancer

October 19th 2020

The first patient has officially been dosed with investigational anti-Dickkopf-1 antibody plus tislelizumab with or without chemotherapy as part of the ongoing phase 2a DisTinGuish study (NCT04363801) in patients with gastric or gastroesophageal junction cancer.

Dr. Sun on First-Line Treatment Challenges in Gastric Cancer

October 16th 2020

Weijing Sun, MD, FACP, discusses remaining challenges in the first-line treatment of patients with gastric cancer.

Nivolumab Nears EU Approval for Second-Line Esophageal Squamous Cell Carcinoma

October 16th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for nivolumab in the treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma following previous fluoropyrimidine- and platinum-based chemotherapy.

Ongoing Studies Could Modify the Script in Metastatic Pancreatic Cancer

October 15th 2020

Allyson Ocean, MD, discussed the importance of clinical trials and how they should not be viewed as a last resort for patients with metastatic pancreatic cancer.